Guest Blog by Sharon Ferrer The pharmaceutical landscape continues to get remapped. Between now and 2016, several blockbuster drugs are poised to lose patent protection. This means that the cost of prescription medications will nose-dive for millions of patients (and their insurance companies) as generic competition heats up. In just the next year alone, seven … Continue reading
There’s promising news on the horizon for the treatment of the hepatitis C virus (HCV). The pharmaceutical company Pharmasset has a Phase 2b trial in progress that aims to treat chronic HCV without the use of interferon (and separate arms of the trial are with and without ribavirin). The goal of this QUANTUM Trial is … Continue reading